Curia’s Patented Process for Intermediates Useful for Deucravacitinib
white paper
internal
In this white paper, we describe how Curia’s patented new process can obtain intermediates in the synthesis of compounds such as Deucravacitinib solving the problem of providing a purification method. If you want to learn more, check the asset below or Curia’s patent application WO2025/186427.
Products with existing patent protection are intended for development use and Regulatory Purposes only, under 35 U.S.C. 271(e)(1) and article 10.6 of the Directive 2001/EC as amended by the Directive 2004/27/EC.